betazon 0,5 mg/g krema
jadran galenski laboratorij d.d., svilno 20, rijeka - betametazondipropionat - krema - 0,5 mg/g - urbroj: 1 g kreme sadrži 0,5 mg betametazona u obliku betametazondipropionata
betazon 0,5 mg/g mast
jadran galenski laboratorij d.d., svilno 20, rijeka - betametazondipropionat - mast - 0,5 mg/g - urbroj: 1 g masti sadržava 0,5 mg betametazona u obliku betametazondipropionata
beloderm 0.5 mg/1 g mast
farmavita d.o.o. sarajevo - betamethasone - mast - 0.5 mg/1 g - 1 g masti sadrži: 0,5 mg betametazon (u obliku betametazon dipropionata)
beloderm 0.5 mg/1 g krema
farmavita d.o.o. sarajevo - betamethasone - krema - 0.5 mg/1 g - 1 g kreme sadrži: 0,5 mg betametazon (u obliku betametazon dipropionata)
betazon 0.5 mg/1 g krema
farmis d.o.o. sarajevo - betamethasone - krema - 0.5 mg/1 g - 1 g kreme sadrži: 0,5 mg betametazon (u obliku betametazon dipropionata)
betazon 0.5 mg/1 g mast
farmis d.o.o. sarajevo - betamethasone - mast - 0.5 mg/1 g - 1 g masti sadrži: 0,5 mg betametazon (u obliku betametazon dipropionata)
bethanat 0.5 mg/1 g mast
bosnalijek d.d. - betamethasone - mast - 0.5 mg/1 g - 1 g masti sadrži: 0,5 mg betametazon (u obliku betametazon dipropionata)
beloderm 0.5 mg/1 g krema
farmavita d.o.o. sarajevo - betamethasone - krema - 0.5 mg/1 g - 1 g kreme sadrži: 0,5 mg betametazon (u obliku betametazon dipropionata)
beloderm 0.5 mg/1 g mast
farmavita d.o.o. sarajevo - betamethasone - mast - 0.5 mg/1 g
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - ostali lijekovi protiv živčanog sustava - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.